• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Nautilus Biotechnolgy Inc.

    4/29/25 4:07:31 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $NAUT alert in real time by email
    DEFA14A 1 nautilusdefa14anotice2025a.htm DEFA14A Nautilus DEFA14A Notice 2025

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    _____________________________________________________________________
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    _____________________________________________________________________
    Filed by the Registrant x
    Filed by a Party other than the Registrant ¨

    Check the appropriate box:
    ¨Preliminary Proxy Statement
    ¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ¨Definitive Proxy Statement
    xDefinitive Additional Materials
    ¨Soliciting Material under §240.14a-12
    NAUTILUS BIOTECHNOLOGY, INC.
    (Name of Registrant as Specified In Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
    xNo fee required.
    ¨Fee paid previously with preliminary materials.
    ¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.




    Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V72592-P28492 NAUTILUS BIOTECHNOLOGY, INC. 2025 Annual Meeting Vote by June 19, 2025 11:59 PM ET NAUTILUS BIOTECHNOLOGY, INC. 2701 EASTLAKE AVE EAST SEATTLE, WA 98102-4188 You invested in NAUTILUS BIOTECHNOLOGY, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 20, 2025. Vote Virtually at the Meeting* June 20, 2025 10:00 AM PDT Virtually at: www.virtualshareholdermeeting.com/NAUT2025 Get informed before you vote View the Notice and Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 6, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.


     
    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V72593-P28492 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. Election of Class I Directors For Nominees: 01) Sujal Patel 02) Matthew McIlwain 2. Ratification of the appointment of PricewaterhouseCoopers, LLP as our independent registered public accounting firm for the year ended December 31, 2025. For NOTE: In their discretion, the proxyholders will vote on such other business as may properly come before the meeting or any adjournment or postponement thereof.


     

    Get the next $NAUT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NAUT

    DatePrice TargetRatingAnalyst
    12/5/2024$1.75Neutral → Sell
    Goldman
    6/27/2024$6.00Buy
    Guggenheim
    6/3/2024$3.00Hold
    Jefferies
    1/6/2022$8.00Equal-Weight
    Morgan Stanley
    11/2/2021Outperform
    Cowen & Co.
    8/4/2021$10.00Neutral
    Goldman Sachs
    7/13/2021$13.00Buy
    Jefferies
    More analyst ratings

    $NAUT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

      SEATTLE, May 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the Goldman Sachs 46th Annual Global Healthcare Conference. Nautilus' management is scheduled to participate in a fireside chat on Tuesday, June 10, 2025, at 2:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its research and deve

      5/27/25 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology Reports First Quarter 2025 Financial Results

      SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2025. "In Q1, we saw continued development progress based on the results of internal verification and validation work we've done on our Tau proteoform assay," said Sujal Patel, CEO of Nautilus Biotechnology. "The assay's reproducibility, accuracy, dynamic range, and sample compatibility align closely with our anticipated launch specifications and with the requirements we continue to hear from potential customers and partners. We are confident that 202

      4/29/25 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025

      SEATTLE, April 16, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today announced it will report financial results for the first quarter 2025 before market open on Tuesday, April 29, 2025. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and it

      4/16/25 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $NAUT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO and Treasurer Mowry Anna bought $11,488 worth of shares (15,000 units at $0.77), increasing direct ownership by 22% to 83,000 units (SEC Form 4)

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      6/2/25 5:12:33 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Scientist Mallick Parag bought $9,885 worth of shares (13,500 units at $0.73), increasing direct ownership by 0.07% to 20,493,392 units (SEC Form 4)

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      5/12/25 7:19:33 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • CEO, President, and Secretary Patel Sujal M bought $76,918 worth of shares (77,233 units at $1.00), increasing direct ownership by 0.77% to 10,141,721 units (SEC Form 4)

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      3/21/25 4:44:37 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $NAUT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO and Treasurer Mowry Anna bought $11,488 worth of shares (15,000 units at $0.77), increasing direct ownership by 22% to 83,000 units (SEC Form 4)

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      6/2/25 5:12:33 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Scientist Mallick Parag bought $9,885 worth of shares (13,500 units at $0.73), increasing direct ownership by 0.07% to 20,493,392 units (SEC Form 4)

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      5/12/25 7:19:33 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • CEO, President, and Secretary Patel Sujal M bought $76,918 worth of shares (77,233 units at $1.00), increasing direct ownership by 0.77% to 10,141,721 units (SEC Form 4)

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      3/21/25 4:44:37 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $NAUT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Nautilus Biotechnology downgraded by Goldman with a new price target

      Goldman downgraded Nautilus Biotechnology from Neutral to Sell and set a new price target of $1.75

      12/5/24 7:46:35 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Guggenheim initiated coverage on Nautilus Biotechnology with a new price target

      Guggenheim initiated coverage of Nautilus Biotechnology with a rating of Buy and set a new price target of $6.00

      6/27/24 7:49:37 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Jefferies resumed coverage on Nautilus Biotechnology with a new price target

      Jefferies resumed coverage of Nautilus Biotechnology with a rating of Hold and set a new price target of $3.00

      6/3/24 8:53:10 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $NAUT
    SEC Filings

    See more
    • Nautilus Biotechnolgy Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)

      5/2/25 4:30:28 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Nautilus Biotechnolgy Inc.

      DEFA14A - Nautilus Biotechnology, Inc. (0001808805) (Filer)

      4/29/25 4:07:31 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEF 14A filed by Nautilus Biotechnolgy Inc.

      DEF 14A - Nautilus Biotechnology, Inc. (0001808805) (Filer)

      4/29/25 4:06:20 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $NAUT
    Financials

    Live finance-specific insights

    See more
    • Nautilus Biotechnology Reports First Quarter 2025 Financial Results

      SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2025. "In Q1, we saw continued development progress based on the results of internal verification and validation work we've done on our Tau proteoform assay," said Sujal Patel, CEO of Nautilus Biotechnology. "The assay's reproducibility, accuracy, dynamic range, and sample compatibility align closely with our anticipated launch specifications and with the requirements we continue to hear from potential customers and partners. We are confident that 202

      4/29/25 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025

      SEATTLE, April 16, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today announced it will report financial results for the first quarter 2025 before market open on Tuesday, April 29, 2025. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and it

      4/16/25 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results

      SEATTLE, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2024. Reported total operating expenses for the fourth quarter of 2024 were $20.0 million, roughly equal to the fourth quarter of 2023, and $0.9 million above last quarter reflecting an ongoing focus on expense management;Announced an expectation that the launch of Nautilus' proteome analysis platform - instruments and reagents - will occur in late 2026;Announced a reduction in headcount of approximately 16% in order to appropriat

      2/27/25 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $NAUT
    Leadership Updates

    Live Leadership Updates

    See more
    • Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer

      SEATTLE, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for comprehensively quantifying the proteome, today announced the appointment of Kentaro (Ken) Suzuki as Chief Marketing Officer. Mr. Suzuki joins Nautilus after 25 years in product and marketing leadership roles at Agilent Technologies, most recently serving as Vice President and General Manager of Agilent's Mass Spectrometry division. He has held numerous leadership positions at Agilent, including in the Strategic Program Office and Certified Pre-Owned Instruments, CrossLab Services and Support, and Spectroscopy. "Ke

      9/17/24 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development

      SEATTLE, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the expansion of its research and development senior leadership team with the appointment of Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development. Dr. Huber brings to Nautilus over 20 years of experience in biotechnology start-ups both in Europe and the US, most recently as founder, CTO and, ultimately, CEO of Quantapore, a company devoted to pioneering massively parallel, direct, single-molecule DNA and protein analytical tools. Prior to that, he he

      11/1/23 8:05:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology Appoints Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development

      SEATTLE, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced further expansion of its management team with the appointments of Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development. Both executives join the company's product development team. Eric Spence, Vice President of Instrument Engineering: Instrument engineering veteran Eric Spence comes to Nautilus from Genapsys, where he advanced through several positions of increasing responsibility leading the instrum

      8/1/22 4:05:00 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $NAUT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Nautilus Biotechnolgy Inc.

      SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      11/14/24 4:31:50 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13D/A filed by Nautilus Biotechnolgy Inc. (Amendment)

      SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      11/16/23 9:18:26 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13D/A filed by Nautilus Biotechnolgy Inc. (Amendment)

      SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      3/1/23 3:30:45 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials